Genitourinary Cancer

Top Story

FDA grants accelerated approval to Keytruda for solid tumors with specific biomarker

May 23, 2017

The FDA today granted accelerated approval to pembrolizumab for adults and children with unresectable or metastatic, microsatellite instability–high or mismatch repair–deficient solid tumors.

This indication for pembrolizumab (Keytruda, Merck) — the FDA’s first tissue/site-agnostic approval — includes patients with solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options, as well as patients with colorectal cancer that has progressed following treatment with fluoropyrimidine, oxaliplatin and irinotecan.

In the Journals Plus

Rare cancers represent 20% of US cancer diagnoses

May 19, 2017
Rare malignancies accounted for about one in five cancer diagnoses in the United States from 2009 to 2013, according to an American Cancer Society report published in…
FDA News

FDA approves Keytruda for advanced urothelial carcinoma

May 18, 2017
The FDA granted accelerated and regular approval to pembrolizumab for the first- and second-line treatments of locally advanced or metastatic urothelial carcinoma…
Video

VIDEO: Mini open tumor resection and percutaneous instrumentation for T11 renal cell carcinoma

May 16, 2017
In this video from the Open Operating Theatre, Yann Philippe Charles, MD, from University Hospital in Strasbourg, France, discusses how to perform a…
CME

Breakthroughs in the Treatment of Bladder Cancer

This activity is supported by an educational grant from Bristol-Myers Squibb.

Assessment of immune checkpoint blockade inhibitors in the treatment of bladder cancer have demonstrated significant…
More »
Video
Meeting News Coverage

VIDEO: CABOSUN trial ‘changes the game’ of first-line renal cell carcinoma therapy

October 12, 2016
More »
Featured
ASCO Annual Meeting

ASCO Annual Meeting

CME

What's Hot in Melanoma? Highlights from the HemOnc Today Melanoma and Cutaneous Malignancies 2017 Meeting

This activity is supported by an educational grant from Merck & Co, Inc.

The development and integration of targeted therapies, as well as immunotherapies, into clinical strategies for the…
More »
FDA News

FDA grants accelerated approval to Keytruda for solid tumors with specific biomarker

May 23, 2017
The FDA today granted accelerated approval to pembrolizumab for adults and children with unresectable or metastatic, microsatellite…

In the Journals Plus

Rare cancers represent 20% of US cancer diagnoses

May 19, 2017
Rare malignancies accounted for about one in five cancer diagnoses in the United States from 2009 to 2013, according to an American Cancer Society…

FDA News

FDA approves Keytruda for advanced urothelial carcinoma

May 18, 2017
The FDA granted accelerated and regular approval to pembrolizumab for the first- and second-line treatments of locally advanced or metastatic…

Video

VIDEO: Mini open tumor resection and percutaneous instrumentation for T11 renal cell carcinoma

May 16, 2017
In this video from the Open Operating Theatre, Yann Philippe Charles, MD, from University Hospital in Strasbourg, France

FDA News

FDA grants breakthrough therapy designation to entrectinib for NTRK fusion–positive solid tumors

May 15, 2017
The FDA granted breakthrough therapy designation to entrectinib for the treatment of NTRK fusion–positive locally advanced or metastatic solid…

Meeting News

E-cigarettes may increase bladder cancer risk

May 15, 2017
A high percentage of urine samples from electronic cigarette users tested positive for two known bladder carcinogens, according to results of a pilot…

Seven updates in bladder cancer

May 12, 2017
May is Bladder Cancer Awareness Month to promote public awareness programs, increase education and enable the bladder cancer community to get…

FDA News

FDA grants orphan drug designation to larotrectinib for solid tumors with NTRK gene fusions

May 12, 2017
The FDA granted orphan drug designation to larotrectinib for the treatment of solid tumors with neurotrophic tyrosine receptor kinase–fusion…

Confirmatory study of atezolizumab for advanced bladder cancer fails to meet primary endpoint

May 10, 2017
A randomized phase 3 trial that evaluated atezolizumab for treatment of locally advanced or metastatic urothelial cancer failed to meet its primary…

FDA News

FDA grants accelerated approval to Bavencio for advanced urothelial carcinoma

May 9, 2017
The FDA granted accelerated approval to avelumab for the treatment of locally advanced or metastatic urothelial carcinoma, according to the…

More Headlines »
Advertisement
Advertisement